Innovative Immunology Biotech Windward Bio Lists on Nasdaq

Detailed summary

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on…

SHANGHAI, Nov. 14, 2026 /PRNewswire/ -- Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners' 11th IPO in 2026.

Qiming Venture Partners invested in Windward Bio's inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.

Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Windward Bio's lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company's pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases.

"Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.